Based on the CTX310 data, it looks to have a clean safety profile. There were no SAEs, no grade =3 AEs, and no clinically significant changes in either liver enzymes (ALT, AST and/or bilirubin) or platelets across all dose levels. However, just ten patients across all four dose cohorts were treated. The data shows minimal activity at DL1 and DL2, but meaningful responses at DL3 and DL4. A single patient at the highest dose level achieved the most impressive reductions, indicating they could take this into the phase one(b).
Market Data 
Markets 
AI
